Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6


Is Dipstick Urinalysis Screening Beneficial in Men with Lower Urinary Tract Symptoms?

Lowe FC, Michel MC, Wruck JM, Verbeek AE.

Adv Ther. 2019 Aug 7. doi: 10.1007/s12325-019-01042-0. [Epub ahead of print]


Management of Male Lower Urinary Tract Symptoms in a Simulated, Over-the-Counter Setting: An Exploratory Study of Tamsulosin.

Roehrborn CG, Lowe FC, Gittelman M, Wruck JM, Verbeek AE.

Drugs Aging. 2019 Feb;36(2):179-188. doi: 10.1007/s40266-018-0621-8.


Feasibility of an Alternative Option for the Management of Male Lower Urinary Tract Symptoms.

Roehrborn CG, Lowe FC, Gittelman M, Wruck JM, Verbeek AE.

J Urol. 2016 Jan;195(1):125-30. doi: 10.1016/j.juro.2015.08.098. Epub 2015 Sep 10. Erratum in: J Urol. 2016 Mar;195(3):807. J Urol. 2016 Mar;195(3):807.


Pharmacokinetic interactions between buprenorphine/naloxone and tipranavir/ritonavir in HIV-negative subjects chronically receiving buprenorphine/naloxone.

Bruce RD, Altice FL, Moody DE, Lin SN, Fang WB, Sabo JP, Wruck JM, Piliero PJ, Conner C, Andrews L, Friedland GH.

Drug Alcohol Depend. 2009 Dec 1;105(3):234-9. doi: 10.1016/j.drugalcdep.2009.07.007. Epub 2009 Sep 1.


Pharmacokinetic assessment of nevirapine and metabolites in human immunodeficiency virus type 1-infected patients with hepatic fibrosis.

Cammett AM, MacGregor TR, Wruck JM, Felizarta F, Miailhes P, Mallolas J, Piliero PJ.

Antimicrob Agents Chemother. 2009 Oct;53(10):4147-52. doi: 10.1128/AAC.00460-09. Epub 2009 Jul 20.


Steady-state disposition of the nonpeptidic protease inhibitor tipranavir when coadministered with ritonavir.

Chen L, Sabo JP, Philip E, Mao Y, Norris SH, MacGregor TR, Wruck JM, Garfinkel S, Castles M, Brinkman A, Valdez H.

Antimicrob Agents Chemother. 2007 Jul;51(7):2436-44. Epub 2007 May 7.

Supplemental Content

Loading ...
Support Center